We are a global leader in exploiting a novel class of untapped, aberrantly expressed tumour-specific antigens (aeTSAs) or CryptigenTM TSAs that are shared across multiple patients with the same tumor type, for the development of off-the-shelf cancer vaccines across the landscape of difficult to treat cancers.
Epitopea is a transatlantic cancer immunotherapeutics company based in Montreal, Canada and Cambridge, UK.
Our proprietary CryptoMapTM platform, created and optimized by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer, at the Université de Montréal, identifies shared, aberrantly expressed tumour-specific antigens (aeTSAs), known as CryptigenTM TSAs, that are hidden in ‘junk DNA’.
